Scientific programme

The scientific programme is structured around basic science, translational medicine and clinical sessions, given by some of the world’s top specialists. It includes oral presentations of the best abstracts, the announcement of ECCO Fellowships and Grants and summary presentations of new ECCO Guidelines. The focus of all sessions is clinical practice founded on science, with practical messages to take home.
Scientific sessions are held from Thursday to Saturday, March 7-9, 2019. The congress registration fee includes access to all scientific sessions.

Research drives clinical care

  • Plenary hall

    Industry sponsored satellite symposia 1a, 1b, & 1c
    12:15-12:25 1: Opening
    Silvio Danese, Milan, Italy
    12:25-12:30  2: Welcome
    President of Dansk Selskab for Gastroenterologi og Hepatologi
    Henning Glerup, Silkeborg, Denmark
    Scientific session 1: Silencing IBD
    Peter Irving, London, United Kingdom
    Britta Siegmund, Berlin, Germany
      12:30-12:50 3: Can we prevent IBD?
    Jean-Frédéric Colombel, New York, United States
      12:50-13:00 4: OP01: In-depth characterisation of host-genetics and gut microbiome unravels novel host-microbiome interactions in Inflammatory Bowel Disease
    S. Hu1, A. Vich Vila1, R. Gacesa1, V. Collij1, R. Xavier2, C. Stevens3, M. Daly3, C. Wijmenga4, H. van Dullemen1, G. Dijkstra1, M. Visschedijk1, E. Festen1, J. Fu5, A. Kurilshikov4, A. Zhernakova4, R. Weersma1

    1Universitair Medisch Centrum Groningen, Gastroenterology & Hepatology, Groningen, Netherlands, 2Massachusetts General Hospital, Molecular Biology, Boston, United States, 3Broad Institute, Boston, United States, 4Universitair Medisch Centrum Groningen, Genetics, Groningen, Netherlands, 5Universitair Medisch Centrum Groningen, Pediatrics, Groningen, Netherlands
    5: Can we cure IBD?
    Arthur Kaser, Cambridge, United Kingdom
      13:20-13:30 6: OP02: The role of PTPN2 SNP in the pathogenesis of fibrosis in Crohn’s Disease
    C. Li, J. Kuemmerle
    Virginia Commonwealth University, Internal Medicine, Richmond, United States
    13:30-13:40 7: OP03: Inhibition of autophagy exacerbates intestinal fibrosis and EMT
    J. Cosin-Roger1,2, D. Ortiz-Masia3, F. Canet1, A. Trescoli-Garcia1, S. Calatayud1, M. D. Barrachina1
    1University of Valencia, Pharmacology, Valencia, Spain, 2Hospital Dr Peset, Valencia, Spain, 3University of Valencia, Medicine, Valencia, Spain
    13:40-14:00 8: Are fibrotic complications reversible?
    Geert D'Haens, Amsterdam, The Netherlands
    Massimo Pinzani, London, United Kingdom
    14:00-14:30 Coffee break 
    14:30-16:00 Scientific session 2: Complementary treatments: The good and the bad
    Shomron Ben-Horin, Tel Aviv, Israel
    Pascal Juillerat, Bern, Switzerland
      14:30-14:50 9: The crazy stuff - what your patients are taking and why?
    Fernando Gomollón Garcia, Zaragoza, Spain
      14:50-15:00 10: OP04: Turning sweet in Inflammatory Bowel Disease: Glycans as novel immunomodulators of T cell-mediated immune response
    A. Dias1, M. Pereira1, A. Correia1, I. Alves1, V. Pinto1, L. Azevedo2, L. Maia3, R. Marcos-Pinto3, M. Vilanova1, P. Lago3, S. Pinho1
    Institute for Research and Innovation in Health (i3S), Immunology, Cancer & GlycoMedicine, Porto, Portugal, 2Medical Faculty, Department of Community Medicine, Information and Health Decision Sciences, Porto, Portugal, 3Porto Centre Hospital, Gastroenterology, Porto, Portugal
      15:00-15:20 11: ECCO Topical Review on complementary medicine
    Joana Torres, Lisbon, Portugal
    Stephan Vavricka, Zurich, Switzerland
      15:20-15:30 12: OP05: Crohn’s Disease exclusion diet is equally effective but better tolerated than exclusive enteral nutrition for induction of remission in Mild to Moderate Active Paediatric Crohn’s Disease: A prospective randomised controlled trial
    J. Van Limbergen1, 2, E. Wine3, A. Assa4, R. Sigall Boneh5, R. Shaoul6, M. Kori7, S. Cohen8, S. Peleg9, H. Shamaly10, A. On11, P. Milman12, L. Abramas5, T. Ziv Baran13, S. Grant14, A. Levine5, 13
    1Dalhousie University, Halifax, Canada, 2IWK Center, Halifax, Canada, 3University Alberta, Edmonton, Canada, 4Schneider Medical Center, Petach Tikva, Israel, 5Wolfson Medical Center, Holon, Israel, 6Meyer Hospital, Haifa, Israel, 7Kaplan Hospital, Rehovot, Israel, 8Dana childrens Hospital, Tel Aviv, Israel, 9HaEmek Hospital, Afula, Israel, 10French Hospital, Nazareth, Israel, 11Poriah Hospital, Tiberias, Israel, 12Hadassah Hospital, Jerusalem, Israel, 13Tel Aviv University, Tel Aviv, Israel, 14Mount Saint Vincent University, Halifax, Canada
      15:30-15:40 13: OP06: Gut-brain-axis revisited: Shedding light on the mucosa associated microbial composition in IBD patients with psychological distress, anxiety and depression
    F. Humbel1, P. Juillerat2, M. Scharl1, B. Misselwitz2, P. Schreiner1, A. Macpherson2, G. Rogler1, R. von Känel3, B. Yilmaz4, 5, L. Biedermann1, 5
    University Hospital Zurich, Department of Gastroenterology & Hepatology, Zurich, Switzerland, 2Bern University Hospital, Department of Visceral Surgery and Medicine, Bern, Switzerland, 3University Hospital Zurich, Consultation-Liaison Psychiatry and Psychosomatic Medicine, Zurich, Switzerland, 4University of Bern, Maurice Müller Laboratories, Bern, Switzerland, 5*Equal, Contribution, Switzerland
      15:40-16:00 14: Psychological support in IBD
    Yoram Inspector, London, United Kingdom
    16:00-17:20 Scientific session 3: Precision medicine: Lessons to learn and paths to the future
    Axel Dignass, Frankfurt am Main, Germany
    Jesús Rivera-Nieves, San Diego, United States
    16:00-16:20 15: What is system biology?
    Dermot McGovern, Los Angeles, United States
    16:20-16:40 16: Multi-omics profiling of IBD
    Jonas Halfvarson, Örebrö, Sweden
    16:40-16:50 17: OP07: Analysing intestinal organoids in a multi-omics, systems biology framework to investigate functional processes affected in Crohn’s Disease due to autophagy impairment
    L. Gul1, E. Jones1, 2, Z. Matthews3, P. Sudhakar1, 2, 4, A. Treveil1, 2, D. Divekar2, 3, J. Buck3, M. Jefferson3, S. Armstrong5, A. Watson2, 3, S. Carding2, 3, U. Mayer6, P. Powell3, I. Hautefort1, T. Wileman2, 3, T. Korcsmaros1, 2
    Earlham Institute, Norwich, United Kingdom, 2Quadram Institute, Norwich, United Kingdom, 3Norwich Medical School, University of East Anglia, Norwich, United Kingdom, 4KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 5University of Liverpool, National Institute of Health Research, Liverpool, United Kingdom, 6School of Biological Sciences, University of East Anglia, Norwich, United Kingdom
    16:50-17:00 18: OP08: Long-term efficacy and pharmacodynamics of the anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) monoclonal antibody SHP647 in Crohn’s Disease: The OPERA II study
    G. D'Haens1, W. Reinisch2, S. D. Lee3, D. Tarabar4, E. Louis5, M. Kłopocka6, J. Klaus7, S. Schreiber8, D. I. Park9, X. Hébuterne10, K. J. Gorelick11, S. W. Martin12, A. Banerjee12, P. Nagy13, Y. Wang14, F. Cataldi14, W. J. Sandborn15
    1Academic Medical Centre, Amsterdam, Netherlands, 2Medical University of Vienna, Vienna, Austria, 3University of Washington, Seattle, WA, United States, 4Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, 5University Hospital of Liège, Liège, Belgium, 6Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 7University Hospital Ulm, Ulm, Germany, 8University Hospital Schleswig-Holstein, Christian-Albrechts-University of Kiel, Kiel, Germany, 9Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea, 10University of Nice Sophia Antipolis, Hospital l'Archet, Nice, France, 11Zymo Consulting Group, Newtown Square, PA, United States, 12Pfizer, Cambridge, MA, United States, 13Shire, Zug, Switzerland, 14Shire, Lexington, MA, United States, 15University of California San Diego, La Jolla, CA, United States
    17:00-17:20 19: Stratifying by disease biology to choose the right drug for the right patient
    Charlie Lees, Edinburgh, United Kingdom
    17:30-18:30 Digital Oral Presentations Sessions 1-5
    Industry sponsored satellite symposia 2a, 2b, & 2c
  • Plenary hall

    07:15-08:15 Industry sponsored satellite symposia 3b & 3c
    08:30-10:30 Scientific session 4: Best practice in UC
    Andre D'Hoore, Leuven, Belgium
    Henit Yanai, Petah Tikva, Israel
    08:30-08:50 20: When do you start a biologic?
    Simon Travis, Oxford, United Kingdom
    08:50-09:00 21: OP09: Histological remission and mucosal healing in a randomised, placebo-controlled, phase 2 study of etrasimod in patients with Moderately to Severely Active Ulcerative Colitis
    L. Peyrin-Biroulet
    1, J. Panés2, M. Chiorean3, J. Zhang4, S. Vermeire5, V. Jairath6, A. Yarur7, C. Cabell4, S. Naik4, W. J. Sandborn8
    1University Hospital of Nancy, Vandœuvre-lès-Nancy, France, 2Hospital Clinic of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 3Virginia Mason Medical Center, Seattle, United States, 4Arena Pharmaceuticals, Inc., San Diego, United States, 5University Hospitals Leuven, Leuven, Flanders, Belgium, 6Western University, London, Ontario, Canada, 7Medical College of Wisconsin, Milwaukee, United States, 8University of California San Diego, La Jolla, United States
    09:00-09:10 22: OP10: Systems genomics of Ulcerative Colitis: Combining GWAS and signalling networks for patient stratification and individualised drug targeting in Ulcerative Colitis
    J. Brooks1,2, D. Modos3, P. Sudhakar4, 5, D. Fazekas4, 6, A. Zoufir3, A. Watson1, 7, M. Tremelling1, B. Verstockt8, S. Vermeire8, A. Bender3, S. Carding2, 7, T. Korcsmaros2, 4
    1Norfolk and Norwich University Hospital, Gastroenterology, Norwich, United Kingdom, 2The Quadram Institute Bioscience, Gut Microbes and Health Programs, Norwich, United Kingdom, 3Centre for Molecular Science Informatics, Department of Chemistry University of Cambridge, Cambridge, United Kingdom, 4Earlham Institute, Norwich Research Park, Norwich, United Kingdom, 5KU Leuven,, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, 6Eötvös Loránd, Department of Genetics, Budapest, Hungary, 7University of East Anglia, Norwich Medical School, Norwich, United Kingdom, 8University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium
    09:10-09:20 23: OP11: Organoids derived from inflamed intestinal biopsies of patients with Ulcerative Colitis lose their inflammatory phenotype during ex vivo culture
    K. Arnauts1, 2, B. Verstockt1, 3, M. Vancamelbeke1, S. Vermeire1, 3, C. Verfaillie2, M. Ferrante1, 3 1KU Leuven, Department of Chronic Diseases, Metabolism & Ageing (CHROMETA), Leuven, Belgium, 2KU Leuven, Department of Development and Regeneration, Leuven, Belgium, 3KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium
    09:20-09:40 24: Where is the exit?
    Marc Ferrante, Leuven, Belgium
    09:40-09:50 25: OP12: Targeting inflammation in Ulcerative Colitis by inhibiting glucose uptake
    R. Gropp1, H. Jodeleit1, J. Caesar1, C. Villarroel Aguilera1, F. Beigel2, 3, S. Breiteneicher3, J. Stallhofer3, M. Siebeck1
    Hospital of the Ludwig Maximilian University, General-, Visceral-, Vascular- and Transplantation Surgery, Munich, Germany, 2Hospital of the Ludwig Maximilian University, Laboratory Medicine, Munich, Germany, 3Hospital of the Ludwig Maximilian University, Medicine II, Munich, Germany

    09:50-10:00 26: OP13: Molecular response to ustekinumab in Moderate to Severe Ulcerative Colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI phase 3 induction study
    K. Li, F. Yang, K. Hayden, D. Strawn, E. Wadman, S. Bhagat, C. Marano, J. R. Friedman
    Janssen Research & Development, LLC, Spring House, United States
    10:00-10:10 27: OP14: Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with Moderately to Severely Active Ulcerative Colitis: Data from the U-ACHIEVE study
    W. J. Sandborn
    1, S. Schreiber2, S. D. Lee3, J. O. Lindsay4, X. Hebuterne5, W. Zhou6, F. Cataldi6, A. P. Lacerda6, B. Huang6, W. Xie6, E. V. Loftus Jr7
    University of California San Diego, La Jolla, United States, 2University Hospital Schleswig-Holstein, Kiel, Germany, 3University of Washington, Seattle, United States, 4Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 5Service de Gastroentérologie et Nutrition Clinique, Nice, France; Université de Nice-Sophia-Antipolis, Nice, France, 6AbbVie Inc., North Chicago, United States, 7Mayo Clinic, Rochester, United States
      10:10-10:30 28: Precision surgery in UC
    Yves Panis, Clichy, France
    10:30-11:00 Coffee Break
    11:00-12:30 Scientific session 5: IBD around the world
    Toshifumi Hibi, Tokyo, Japan
    Giovanni Maconi, Milan, Italy
    11:00-11:20 29: Vaccination and travelling with IBD: An update
    Jean-François Rahier, Yvoir, Belgium
    11:20-11:30 30: OP15: Cost-analysis in a prospective European population-based inception cohort. Is there a cost-saving effect of biological therapy?
    J. Burisch
    1, H. Vardi2, D. Schwartz3, Z. Krznaric4, P. L. Lakatos5, M. Fumery6, L. Kupcinskas7, F. Magro8, E. Belousova9, P. Oksanen10, N. Arebi11, E. Langholz12, S. Turcan13, R. D'Inca14, V. Hernandez15, D. Valpiani16, Z. Vegh5, M. Giannotta17, K. H. Katsanos18, D. Duricova19, K. R. Nielsen20, H. A. L. Kievit21, P. Ellul22, R. Salupere23, A. Goldis24, I. Kaimakliotis25, N. Pedersen26, V. Andersen27, J. Halfvarson28, S. Sebastian29, J. F. Dahlerup30, P. Munkholm1, S. Odes3, Epi-IBD
    1North Zealand University Hospital, Frederikssund, Denmark, 2Ben Gurion University of the Negev, Beer Sheva, Israel, 3Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel, 4University Hospital Center Zagreb, Zagreb, Croatia, 5Semmelweis University, Budapest, Hungary, 6Amiens University and Hospital, Amiens, France, 7Lithuanian University of Health Sciences, Kaunas, Lithuania, 8Hospital de São João, Porto, Portugal, 9Moscow Regional Research Clinical Institute, Moscow, Russian Federation, 10Tampere University Hospital, Tampere, Finland, 11Imperial College London, London, United Kingdom, 12Herlev University Hospital, Herlev, Denmark, 13State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Moldova, Republic of, 14Azienda Ospedaliera di Padova, Padova, Italy, 15Complexo Hospitalario Universitario de Vigo, Vigo, Spain, 16Morgagni Hospital, Forli, Italy, 17Careggi Regional Referral Center for Inflammatory Bowel Disease, Florence, Italy, 18University Hospital, Ioannina, Greece, 19Charles University, Prague, Czech Republic, 20National Hospital of the Faroe Islands, Torshavn, Faroe Islands, 21Herning Hospital, Herning, Denmark, 22Mater Dei Hospital, Msida, Malta, 23Tartu University Hospital, Tartu, Estonia, 24University of Medicine ‘Victor Babes’, Timisoara, Romania, 25American Gastroenterology center, Nicosia, Cyprus, 26Slagelse Hospital, Department of medicine, Denmark, 27Regional Hospital of Viborg, Viborg, Denmark, 28Örebro University, Örebro, Sweden, 29Hull and East Yorkshire NHS Trust, Hull, United Kingdom, 30Aarhus University Hospital, Aarhus, Denmark
    11:30-11:50 31: Management of IBD outside of Europe: The example of India
    Rupa Banerjee, Hyderabad, India
    11:50-12:00 32: OP16: A randomised, multicentre, double-blind, placebo-controlled study of a targeted release oral cyclosporine formulation in the treatment of Mild to Moderate Ulcerative Colitis: Efficacy results
    S. Bloom1, T. Iqbal2, C. Nwokolo3, M. Smith4, D. O'Donoghue5, J. Hall6, B. Dzyngel6
    University College London Hospitals, London, United Kingdom, 2Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, 3University Hospital Coventry & Warwickshire, Coventry, United Kingdom, 4Shrewsbury and Telford Hospital, Shrewsbury, United Kingdom, 5St Vincent’s University Hospital, Centre for Colorectal Disease, Dublin, Ireland, 6Sublimity Therapeutics, Solana Beach, United States
      12:00-12:10 33: OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies
    R. Huang1, H. Irizar2, R. Kosoy3, W.-m. Song3, A. Dinarzo3, K. Hao3, J. Rogers4, A. Atreja4, M. Mahajan3, A. Stojmirovic5, J. Perrigoue5, C. Brodmerkel5, S. Plevy5, J. Friedman5, J.-F. Colombel4, M. Dubinsky4, B. Sands4, E. Schadt3, A. Kasarskis3, B. Losic3, C. Argmann3, M. Suarez-Farinas1, 3
    Icahn School at Mount Sinai, Department of Population, Health Science and Policy, New York, United States, 2University College of London, London, United Kingdom, 3Icahn School at Mount Sinai, Department of Genetics and Genomic Science, New York, United States, 4Icahn School at Mount Sinai, Department of Medicine, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, New York City, United States, 5Janssen Research & Development, Janssen Biotech, Johnson & Johnson, Spring House, United States
    12:10-12:30 34: East meets West: Epidemiology of IBD
    Johan Burisch, Copenhagen, Denmark
    Siew Ng, Hong Kong, China
    12:30-13:30 Break
    12:30-13:30 Guided poster session
    Educational Lunchtime Satellite Smposia LS1, LS2, LS3, & LS4
    13:30-14:40 Scientific session 6: New ways of doing endoscopy and imaging in IBD
    Hankje Escher, Rotterdam, The Netherlands
    Christian Maaser, Lüneburg, Germany
    13:30-13:50 35: Assessing bowel damage in CD from adult to childhood
    Anne Griffiths, Toronto, Canada
    13:50-14:00 36: OP18: Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn’s Disease: The paediatric Crohn's Disease adalimumab level-based optimisation treatment (PAILOT) trial
    A. Assa1, M. Matar2, D. Turner3, E. Broide4, B. Weiss5, O. Ledder6, A. Guz Mark2, F. Rinawi2, S. Cohen7, C. Topf Olivestone8, R. Shaoul9, B. Yerushalmi10, R. Shamir2
    Schneider Children's Hospital, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, 2Schneider Children's medical Center, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, 3Shaare Zedek Medical Center, Gastroenterology, Nutrition and Liver Diseases, Jerusalem, Israel, 4Assaf Harofeh, Pediatric Gastroenterology, Zerifin, Israel, 5Sheba Medical Center, Pediatric Gastroenterology, Ramat Gan, Israel, 6Shaare Zedek Medical Center, Pediatric Gastroenterology, Nutrition and Liver Diseases, Jerusalem, Israel, 7Tel Aviv Medical Center, Pediatric Gastroenterology, Tel-Aviv, Israel, 8Kaplan Medical Center, Pediatric Gastroenterology, Rehovot, Israel, 9Rambam Medical center, Pediatric Gastroenterology, Haifa, Israel, 10Soroka Medical Center, Pediatric Gastroenterology, Beer Sheva, Israel
      14:00-14:20 37: Best practice in screening for dysplasia
    Marietta Iacucci, Birmingham, United Kingdom
    14:20-14:30 38: OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve Ulcerative Colitis
    Y. Haberman1, 2, R. Karns2, P. Dexheimer2, M. Schirmer3, T. Braun1, M. Collins2, A. Mo4, M. Rosen2, N. Gotman5, PROTECT Study group, S. Kugathasan6, T. D. Walters7, G. Gibson4, S. Davis Thomas5, C. Huttenhower8, R. J. Xavier9, J. S. Hyams10, L. A. Denson2
    Sheba Medical Center, Tel Hashomer, Israel, 2Cincinnati Children Hospital Medical Center, Cincinnati, United States, 3Broad Institute of MIT and Harvard University, Cambridge, United States, 4Georgia Institute of Technology, Atlanta, United States, 5University of North Carolina, Chapel Hill, United States, 6Emory University, Atlanta, United States, 7Hospital For Sick Children, Toronto, Canada, 8Harvard School of Public Health, Boston, United States, 9Broad Institute of MIT and Harvard University, Boston, United States, 10Connecticut Children’s Medical Center, Hartford, United States
    14:30-14:40 39: OP20: Mucosal microRNA profiles predict response to autologous stem-cell transplantation in Crohn’s Disease
    A. Lewis
    1, R. Jeffrey1, T. Kumagai1, C. J. Hawkey2, M. M. Clark2, M. Allez3, J. Satsangi4, G. Rogler5, A. Silver1, J. O. Lindsay6
    Blizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Genomics and Child Health, London, United Kingdom, 2Centre for Digestive Diseases, Queens Medical Centre, Nottingham, United Kingdom, 33Department of Gastroenterology, Hôpital Saint Louis, APHP, INSERM UMRS 1160, Paris Diderot, Sorbonne Paris-Cité Unversity, Paris, France, 4Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, 5Department of Gastroenterology and Hepatology, University Hospital, Zurich, Switzerland, 6Blizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Immunobiology, London, United Kingdom
    14:40-15:10 Coffee break
    15:10-15:55 Scientific session 7: ECCO Fellowships and Grants
    Edouard Louis, Liège, Belgium
    Janneke van der Woude, Rotterdam, The Netherlands
    15:10-15:17 40: Outcomes from ECCO Pioneer Award 2017: Faecal transplantation using a novel conditioning method for donor and recipient in mild to moderate treatment refractory colitis in Inflammatory Bowel Disease
    Arie Levine, Tel Aviv, Israel
    15:17-15:24 41: Outcomes from the ECCO Fellowship 2018: Role of TNF-inducible gene-6 (TSG-6) in fistulising Crohn's Disease
    Sudharshan Elangovan, Milan, Italy
    15:24-15:31 42: Outcomes from the ECCO Fellowship 2018: Monocyte-derived macrophages as crucial players in the resolution of inflammation and tissue repair in Inflammatory Bowel Disease
    Sales Ibiza, Lisbon, Portugal
    15:31-15:38 43: Outcomes from the ECCO-IOIBD Fellowship 2017: Precision medicine for IBD using advanced machine learning
    Aria Zand, Los Angeles, United States
    15:38-15:45 44: Outcomes from the ECCO-IOIBD Fellowship 2018: Deciphering the gut-specific B cell response in Inflammatory Bowel Disease
    Mathieu Uzzan, Clichy, France
      15:45-15:55 45: Announcement of ECCO Fellowships and Grants 2019
    15:55-16:55 Scientific session 8: IBD Horizons
    Dominik Bettenworth, Münster, Germany
    Janneke N. Samsom, Rotterdam, The Netherlands
    15:55-16:05 46: OP21: ABX464 is safe and efficacious in a proof of concept study in Ulcerative Colitis patients
    S. Vermeire1, X. Hébuterne2, P. Napora3, M. Wisniewska-Jarosinska4, G. Kiss5, A. Bourreille6, Z. Przemysław7, J. Nitcheu8, P. Gineste8, J.-M. Steens8, H. Ehrlich8
    University Hospitals Leuven, Leuven, Belgium, 2CHU Nice Hopital Archet 2, Nice, France, 3Piotr Napora Centrum Badań Klinicznych Lekarze Sp.p., Wroclaw, Poland, 4SANTA FAMILIA, Centrum Badań, Profilaktyki i Leczenia, Lodz, Poland, 5Vasútegészségügyi Nonprofit Közhasznú Kft, Debrecen, Hungary, 6CHU Nantes Hotel Dieu, Nantes, France, 7KO-Med, Lublin, Poland, 8Abivax, Paris, France
    16:05-16:15 47: OP22: Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental Colitis
    M. Barnhoorn1, L. Plug1, E. Muller - de Jonge1, E. Bos2, A. van der Meulen - de Jong1, H. Verspaget1, L. Hawinkels1
    1Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands, 2Leiden University Medical Center, Cell and Chemical Biology, Leiden, Netherlands
    16:15-16:25 48: OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates Colitis in various animal models
    J. Shin
    1, N. Ha1, D. Bae1, D.-h. Suh1, J.-y. Baek1, J. H. Jun1, Y. J. Lee1, Y. I. Choi1, K. H. Ryu1, G. S. Youn2, J. Park2, S.-M. Lee3, S.-k. Seo3, J. W. Lee4, J. S. Kim4, 5
    1Research Institute, Chong Kun Dang Pharmaceutical Corporation, Yongin, South Korea, 2Hallym University, Department of Biomedical Science, Chuncheon, South Korea, 3Inje University College of Medicine, Department of Microbiology and Immunology, Gimhae, South Korea, 4Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, 5Seoul National University Hospital Healthcare System Gangnam Center, Department of Internal Medicine and Healthcare Research Institute, Seoul, South Korea
    16:25-16:35 49: OP24: Effectiveness and safety of ustekinumab 90 mg every four weeks in Crohn's Disease
    M. Fumery
    1, L. Peyrin-biroulet2, S. Nancey3, R. Altwegg4, P. Veyrard5, G. Bouguen6, S. Viennot7, F. Poullenot8, J. Filippi9, A. Buisson10, A. Bozon11, C. Gilletta12, F. Brazier13, L. Pouillon2, B. Flourié14, L. Boivineau4, L. Siproudhis6, D. Laharie8, X. Roblin15, X. Treton11
    Amiens University Hospital, Gastroenterology, AMIENS (80000), France, 2Nancy University Hospital, Gastroenterology, Nancy, France, 3Lyon University Hospital, Lyon, France, 4Montpellier University Hospital, Gastroenterology, Montpellier, France, 5Saint Etienne University Hospital, Gastroenterology, Saint Etienne, France, 6Rennes University Hospital, Gastroenterology, Rennes, France, 7Caen University Hospital, Gastroenterology, Caen, France, 8Bordeaux University Hospital, Gastroenterology, Bordeaux, France, 9Nice University Hospital, Gastroenterology, Nice, France, 10Clermont-Ferrand, Gastroenterology, Clermont Ferrand, France, 11Hopital Beaujon, Gastroenterology, Clichy, France, 12Toulouse University Hospital, Gastroenterology, Toulouse, France, 13Amiens University Hospital, Gastroenterology, Amiens, France, 14Lyon University Hospital, Gastroenterology, Lyon, France, 15Saint Etienne University Hospital, Gastroenterology, Saint-Etienne, France
    16:35-16:45 50: OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s Disease
    E. Dreesen1, F. Baert2, D. Laharie3, P. Bossuyt4, Y. Bouhnik5, A. Buisson6, G. Lambrecht7, E. Louis8, B. Oldenburg9, B. Pariente10, M. Pierik11, C. J. van der Woude12, G. D'Haens13, S. Vermeire14, 15, A. Gils1
    University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 2AZ Delta, Department of Gastroenterology, Roeselare, Belgium, 3Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie et Oncologie Digestive, Bordeaux, France, 4Imelda General Hospital, IBD Clinic, Bonheiden, Belgium, 5Beaujon Hospital, APHP, Paris Diderot University, Department of Gastroenterology, Clichy,, France, 6Estaing University Hospital, Department of Gastroenterology, Clermont-Ferrand, France, 7AZ Damiaan, Department of Gastroenterology, Oostende, Belgium, 8Liège University Hospital, Department of Gastroenterology, Liège, Belgium, 9University Medical Centre, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, 10Huriez Hospital, Lille 2 University,, Department of Gastroenterology and Hepatology, Lille, France, 11University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, Netherlands, 12Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, 13Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands, 14University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 15University of Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium
    16:45-16:55 51: OP26: Long-term safety of vedolizumab in Ulcerative Colitis and Crohn’s Disease: Final results from the GEMINI LTS study
    S. Vermeire1, J.-F. Colombel2, B. G. Feagan3, W. J. Sandborn4, B. E. Sands2, S. Danese5, G. D’Haens6, R. Panaccione7, D. T. Rubin8, I. Shafran9, A. Parfionovas10, R. Rogers10, R. A. Lirio10, E. V. Loftus, Jr11
    1University Hospitals Leuven, Leuven, Belgium, 2Icahn School of Medicine at Mount Sinai, New York, United States, 3Western University, London, Canada, 4University of California San Diego, La Jolla, United States, 5Humanitas University, Milan, Italy, 6Academic Medical Centre, Amsterdam, Netherlands, 7University of Calgary, Calgary, Canada, 8University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States, 9Shafran Gastroenterology Research Center, Winter Park, United States, 10Takeda Pharmaceuticals, Cambridge, United States, 11Mayo Clinic College of Medicine, Rochester, United States
    15:10-16:50 Scientific session 9: Basic Science: Immune cells and microbes: A happy marriage?
    Tim Raine, Cambridge, United Kingdom
    Raja Atreya, Erlangen, Germany
    15:10-15:30 52: Metabolic profiling - the new player in microbiome research
    Stefan Schreiber, Kiel, Germany
    15:30-15:40 53: OP27: High-dimensional mass cytometry reveals the immune cell landscape in Inflammatory Bowel Disease
    V. van Unen1, N. Li1, T. Abdelaal2, 3, Y. Kooy-Winkelaar1, L. Ouboter1, 4, G. Beyrend1, T. Höllt5, 6, L. Mearin7, A. Witte8, H. Escher9, B. Lelieveldt10, 11, A. van der Meulen - de Jong4, F. Koning1
    Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, Leiden, Netherlands, 2Delft University of Technology, Delft Bioinformatics Lab, Delft, Netherlands, 3Leiden University Medical Center, Leiden Computational Biology Center, Leiden, Netherlands, 4Leiden University Medical Center, Department of Gastroenterology, Leiden, Netherlands, 5Leiden University Medical Center, Leiden Computational Biology Centerc, Leiden, Netherlands, 6Delft University of Technology, Computer Graphics and Visualization, Delft, Netherlands, 7Leiden University Medical Center, Department of Paediatrics, Leiden, Netherlands, 8Alrijne Hospital, Department of Gastroenterology, Leiderdorp, Netherlands, 9Erasmus University Medical Center, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, 10Delft University of Technology, Pattern Recognition and Bioinformatics Group, Delft, Netherlands, 11Leiden University Medical Center, Department of LKEB Radiology, Leiden, Netherlands
    15:40-15:50 54: OP28: Host-microbial crosstalk in the pathogenesis of inflammation and cancer in primary sclerosing cholangitis
    M. Neyazi1, N. Ilott2, Oxford IBD Cohort study investigators1, S. Travis1, C. Arancibia1, F. Powrie2, A. Geremia1
    University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom, 2University of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom
    15:50-16:10 55: Using mucosal immune pathways to predict disease outcome
    Ahmed Hegazy, Berlin, Germany
    16:10-16:20 56: OP29: ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer
    L. R. Lopetuso
    1, C. De Salvo, L. Di Martino2, W. Goodman2, F. Scaldaferri3, A. Armuzzi3, A. Gasbarrini1, T. T. Pizarro2
    1Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology Gastroenterological and Oncological Area, Gastroenterological and Endocrino-Metabolical Sciences Department, Roma, Italy, 2Case Western Reserve University, Cleveland, United States, 3Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology Gastroenterological and Oncological Area, Gastroenterological and Endocrino-Metabolical Sciences Department, Roma, Italy
    16:20-16:30 57: OP30: Serum proteomic profiling predicts and diagnoses pouchitis in Ulcerative Colitis patients undergoing ileal pouch-anal anastomosis
    K. Machiels 1 M. Ferrante1, 2, N. Davani1, A. Wolthuis3, A. D'Hoore3, S. Vermeire1, 2
    1KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 2University Hospitals Leuven, Department of gastroenterology and hepatology, Leuven, Belgium, 3University Hospitals Leuven, Abdominal surgery, Leuven, Belgium
    16:30-16:50 58: Resolution pathways: Next frontier to control intestinal inflammation
    Silvia D'Alessio, Milan, Italy
    17:05-18:05 Digital Oral Presentations Sessions 6-10
    18:35-19:35 Industry sponsored satellite symposia 4a, 4c, & 4d
  • Plenary hall

    08:30-10:20 Scientific session 10: The cycle of IBD life in clinical practice
    Glen Doherty, Dublin, Ireland
    Richard Russell, Glasgow, United Kingdom
    08:30-08:50 59: Challenges in managing the elderly
    Guillaume Savoye, Rouen, France
      08:50-09:00 60: OP31: TP53 mutation in human colonic organoids acquires resistance to in vitro long-term inflammation
    K. Tsuchiya
    , S. Watanabe, T. Shirasaki, R. Nishimura, N. Katsukura, S. Hibiya, R. Okamoto, T. Nakamura, M. Watanabe
    Tokyo Medical and Dental University and Dental University and, Tokyo, Japan
      09:00-09:10 61: OP32: A novel mechanism of colonic epithelial-T cell cross-talk is dysregulated in IBD
    R. J. Dart
    1, 2, 3, P. Vantourout1, 2, P. M. Irving3, A. Hayday1, 2
    1King's College London, Peter Gorer Dept of Immunobiology, London, United Kingdom, 2Francis Crick Institute, Immunosurveillance Lab, London, United Kingdom, 3Guy's and St Thomas Hospital, Department of Gastroenterology, London, United Kingdom
      09:10-09:30 62: The reproductive phase: Practical recommendations
    Ailsa Hart, London, United Kingdom
      09:30-09:40 63: OP33: BUB1: A new player in the development of Crohn’s Disease (CD)-associated fibrosis
    V. Garlatti1, F. Ungaro1, S. Spanò1, S. D'Alessio1, 2, S. Danese1, 2
    Humanitas University, Pieve Emanuele, Italy, 2Humanitas Research Hospital, Rozzano, Italy
      09:40-09:50 64: OP34: VARSITY: A Double-Blind, Double-Dummy, Randomised, Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis
    S. Schreiber1, L. Peyrin-Biroulet2, E. V. Loftus Jr.3, S. Danese4, J. Chen5, R. Rogers5, R. A. Lirio5, B. E. Sands6
    University-Hospital Schleswig-Holstein, Kiel, Germany, 2Nancy University Hospital, Nancy, France, 3Mayo Clinic College of Medicine, Rochester, United States, 4Humanitas University, Milan, Italy, 5Takeda Development Center Americas, Inc., Cambridge, United States, 6Icahn School of Medicine at Mount Sinai, New York, United States
      09:50-10:00 65: OP35: Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s Disease: Long-term data from CALM
    C. Yzet
    1,R. Ungaro2, P. Bossuyt3, F. Baert4, T. Vanasek5, G. D'Haens6, V. Joustra6, R. Panaccione7, G. Novacek8, A. Armuzzi9, O. Golovchenko10, O. Prymak10, A. Goldis11, S. Travis12, X. Hébuterne13, M. Ferrante14, G. Rogler15, M. Fumery1, S. Danese16, G. Rydzewska17, B. Pariente18, E. Hertervig19, C. Stanciu20, J.-C. Grimaud21, M.-M. Diculescu22, L. Peyrin-Biroulet23, D. Laharie24, J. P. Wright25, F. Gomollón26, I. Gubonina27, S. Schreiber28, S. Motoya29, P. Hellström30, J. Halfvarson31, J.-F. Colombel2
    Amiens University Hospital, Amiens, France, 2Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, 3IBD Clinic, Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium, 4AZ Delta Roeselare, Roeselare, Belgium, 52-nd Department of Internal Medicine, University Hospital Hradec Králové, Hradec Králové, Czech Republic, 6Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, 7Cumming School of Medicine, University of Calgary, Calgary, Canada, 8Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria, 9Presidio Columbus Fondazione Policlinico A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, 10Medical Clinical Investigational Center of Medical Center Health Clinic LLC, Vinnytsia, Ukraine, 11Universitatea de Medicina si Farmacie, Timisoara, Romania, 12Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, United Kingdom, 13Gastro-Entérologie & Nutrition Clinique, Hopital de l'Archet 2, Nice, France, 14University Hospitals Leuven, Leuven, Belgium, 15Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland, 16Humanitas University, Istituto Clinico Humanitas, Milan, Italy, 17Central Clinical Hospital of the Ministry of Interior in Warsaw, Warsaw, Poland, 18Claude Huriez Hospital, Lille University, Lille, France, 19Skane University Hospital, Lund, Sweden, 20Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania, 21Hepato-Gastroenterology Department, North Hospital, University of Mediterranean, Marseille, France, 22University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, 23Hépato Gastro-Entérologie, Hôpital de Brabois, Nancy, France, 24Hépato-gastroentérologie et d'oncologie digestive, Hôpital Haut-Lévêque, Pessac, France, 25Kingsbury Hospital, Cape Town, South Africa, 26Hospital Clínico de Zaragoza, IIS Aragón, Zaragoza, Spain, 27Military Medical Academy named after S.M.Kirov, Saint-Petersburg, Russian Federation, 28Department of Internal Medicine I, Kiel University, Kiel, Germany, 29IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan, 30Uppsala University Hospital, Uppsala, Sweden, 31Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
      10:00-10:20 66: Cancer risk in children with IBD, an under-recognized issue
    Arie Levine, Tel Aviv, Israel
    10:20-10:50 Coffee Break
    10:50-12:20 Scientific session 11: Towards the future of IBD
    Nik Sheng Ding, Melbourne, Australia
    Marc Ferrante, Leuven, Belgium
    10:50-11:10 67: Artificial intelligence augmenting medical management
    Geert Meyfroidt, Leuven, Belgium
    11:10-11:20 68: OP36: A colonic gene expression signature predicts non-response to anti-inflammatory therapies in Inflammatory Bowel Disease
    T. Sato
    1, K. Li1, K. Hayden1, L. Tomsho1, F. Baribaud1, C. Brodmerkel1, L. E. Greenbaum1, J. R. Friedman1, M. Curran1, Y. Imai2, S. Plevy1, S. E. Telesco1
    1Janssen Research & Development, LLC, Spring House, United States, 2Janssen Pharmaceutical K.K., Tokyo, Japan
    11:20-11:40 69: Robot and surgeon: How will a partnership work?
    Antonino Spinelli, Milan, Italy
    11:40-11:50 70: OP37: Efficacy and safety of ustekinumab as maintenance therapy in Ulcerative Colitis: Week 44 results from UNIFI
    W. J. Sandborn1, B. E. Sands2, R. Panaccione3, C. D. O'Brien4, H. Zhang4, J. Johanns4, L. Peyrin-Biroulet5, G. Van Assche6, S. Danese7, S. R. Targan8, M. T. Abreu9, T. Hisamatsu10, P. Szapary4, C. Marano4
    1University of California San Diego, La Jolla, United States, 2Icahn School of Medicine at Mount Sinai, New York, United States, 3University of Calgary, Calgary, Canada, 4Janssen Research & Development, LLC, Spring House, United States, 5Nancy University Hospital, Université de Lorraine, Nancy, France, 6University of Leuven, Leuven, Belgium, 7Humanitas Research Hospital, Milan, Italy, 8Cedars-Sinai Medical Center, Los Angeles, United States, 9University of Miami Miller School of Medicine, Miami, United States, 10Kyorin University, Tokyo, Japan
    11:50-12:00 71: OP38: Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with Moderately to Severely Active Ulcerative Colitis
    G. R. D'Haens1, W. J. Sandborn2, M. Ferrante3, B. R. Bhandari4, E. Berliba5, T. Hibi6, J. Tuttle7, J. B. Canavan8, S. Friedrich8, M. Durante8, V. Arora8, B. Feagan9
    Amsterdam University Medical Centers, Amsterdam, Netherlands, 2University California San Diego, La Jolla, California, United States, 3UZ Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 4Delta Research Partners, LLC, Bastrop, LA, United States, 5Nicolae Testemițanu State University of Medicine and Pharmacy, Chisinau, Moldova, Republic of, 6Kitasato Institute Hospital Center for Advanced IBD Research and Treatment, Minato-ku, Tokyo, Japan, 7Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California, United States, 8Eli Lilly and Company, Indianapolis, Indiana, United States, 9Western University, Robarts Clinical Trials Inc, London, Ontario, Canada
      12:00-12:20 72: Big data: Potential for transforming IBD research and care
    Ignacio Hernandez-Medrano, Madrid, Spain
    12:20-12:50 Scientific session 12: ECCO Lecture
    Silvio Danese, Milan, Italy
    Laurent Peyrin-Biroulet, Vandoeuvre-Les-Nancy, France
    12:20-12:50 73: ECCO Lecture: Inflammatory cytokines from discoveries to therapies
    Charles Dinarello, Denver, United States
    12:50-12:55 74: Awards and closing remarks
    Silvio Danese, Milan, Italy
    12:55-13:00 75: The ECCO Film 2019